Structure via PubChem · Public domain (PubChem)
semaxanib
Sign in to saveAlso known as SU 5416, SU5416, VEGF receptor 2 kinase inhibitor III, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, (Z)-SU 5416, 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole, 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone, TSU 16
Semaxanib (INN, codenamed SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.
In the Vinony graph
Vinony's link graph records 501 inbound references to semaxanib, and connects out to vascular endothelial growth factor, tyrosine-kinase inhibitor and VEGF receptors.
Vinony files it under Chemical pages without DrugBank identifier, Drugs not assigned an ATC code and Drugs with no legal status.
Vinony links it to 6 Wikipedia language editions.
Chemical data
- Formula
- C15H14N2O
- Molecular weight
- 238.28 g/mol
- IUPAC name
- (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
- SMILES
- CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
- InChIKey
- WUWDLXZGHZSWQZ-WQLSENKSSA-N
- XLogP
- 2.5
- Polar surface area
- 44.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- renal cell carcinoma, mesothelioma, melanoma, cutaneous melanoma
via ChEMBL · EBI
Research
514 papers- Equivalence Study of Semaxanib from Different Suppliers.American journal of respiratory cell and molecular biology · 2020
- Semaxanib, a VEGF inhibitor, suppresses melanogenesis by modulating CRTC3 independently of VEGF signaling.Journal of dermatological science · 2024
- Inactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary Hypertension.Circulation · 2024
- Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension.American journal of physiology. Cell physiology · 2021
- Semaxanib (SUGEN).IDrugs : the investigational drugs journal · 2001
via PubMed
Wikidata facts
- Mass
- 238.111
- Has use
- medication
Show 7 more facts
- subject has role
- protein kinase inhibitors
- chemical formula
- C₁₅H₁₄N₂O
- isomeric SMILES
- CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
- canonical SMILES
- CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
- World Health Organisation international non-proprietary name
- semaxanib
- Commons category
- Semaxanib
- found in taxon
- Streptomyces
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Research
- Synthesis
- See also
- References
Semaxanib (INN, codenamed SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.
==Research==
Excerpted from Wikipedia’s “semaxanib” article, available under the CC BY-SA 4.0 licence.
Available in 6 languages
via Wikidata sitelinks · CC0